BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

April 13, 2026
Posted by: Neeraj Pandey
Category: News

BALAXI PHARMACEUTICALS (BALAXI) Q4 FY26 results are scheduled for May 15, 2026, when the company’s board of directors will approve the financial statements for the January-March 2026 quarter. Trading at Rs 520 as of April 2026 — down -30% from its 52-week high of Rs 780 — the stock has been under pressure alongside its peers in the Pharma Exports / Emerging Markets sector. This Q4 results preview covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook.

BALAXI PHARMACEUTICALS’s Q4 FY26 earnings will be watched for signals on the company’s +15% exports YoY trajectory, and whether operating metrics are recovering toward normalised levels. This article provides a structured preview based on analyst consensus data and publicly available financial information.

Get free investment predictions on Univest.

Table of Contents

BALAXI PHARMACEUTICALS Q4 Results 2026 Date

The BALAXI PHARMACEUTICALS Q4 FY26 results date is May 15, 2026. The board of directors will meet to approve the audited consolidated and standalone financial results for the quarter ended March 31, 2026, and the full year FY2025-26.

Here is a broader view of the Q4 FY26 results calendar for reference:

Company	Results Date	Key Metric
[object Object]	April 9, 2026 (Declared)	FY27 revenue guidance, deal TCV
[object Object]	April 23, 2026	CC growth guidance for FY27
Bharat Electronics (BEL)	May 8, 2026	Order book execution, EBITDA margin
Bharat Forge	May 10, 2026	Global CV + defence execution
BALAXI PHARMACEUTICALS	May 15, 2026	See estimates below

Why Q4 FY26 Matters

Q4 (January-March) is the final quarter of FY26, making it the most important earnings event of the year. Beyond the quarterly numbers, investors will receive: full-year FY26 financial summary, management commentary on FY27 business outlook, and the final dividend recommendation for FY26 shareholders.

For BALAXI PHARMACEUTICALS specifically, Q4 FY26 captures the peak season dynamics of the Pharma Exports / Emerging Markets sector. Management’s commentary on FY27 demand visibility will set the investment narrative for the next 12 months.

BALAXI PHARMACEUTICALS Q4 FY26 Earnings Estimates

BALAXI PHARMACEUTICALS Q4 FY26 analyst consensus estimates — Revenue, PAT, Margin | univest.in

Access premium research on Univest.

Based on publicly available analyst consensus, here are the Q4 FY26 estimates for BALAXI PHARMACEUTICALS:

Metric	Q4 FY26 Estimate	Q3 FY26 Actual	Trend
Revenue	Rs 185 Cr	Rs 162 Cr	QoQ expected improvement
Net Profit (PAT)	Rs 22 Cr	Rs 18 Cr	Normalisation expected
Margin	EBITDA 14%	Q3 FY26 margin	QoQ trend
Volume / Growth Driver	+15% exports YoY	Prior quarter	YoY
Dividend (Expected)	Rs 1 (expected)	FY26 interim dividends	Final dividend

Screen BALAXI PHARMACEUTICALS live fundamentals on the Univest Screener.

Download the Univest iOS App or Univest Android App for real-time Q4 result alerts and analyst updates.

5 Key Factors Driving BALAXI PHARMACEUTICALS Q4 FY26 Performance

1. Africa and CIS Export Growth

Balaxi Pharmaceuticals focuses on exporting branded generic formulations to Africa, the CIS (Commonwealth of Independent States), and Southeast Asia. These markets have growing middle-class populations and increasing healthcare access funding.

2. Branded Generics Premium Margins

Selling branded (rather than pure commodity) generics in export markets commands 30-40% price premium over unbranded alternatives. Balaxi’s brand investment in target markets builds pricing power over time.

3. Regulatory Dossier Paipeline

Filing regulatory dossiers (for product approvals) in new markets builds the future revenue pipeline. New dossier filings and approvals in Q4 would indicate geographic expansion pace.

4. Currency and Political Risk Management

Export to Africa and CIS involves currency volatility and political risk. Balaxi’s ability to manage currency hedging and select stable markets determines export revenue quality.

5. Product Portfolio Depth

Broader therapeutic area coverage (cardiovascular, anti-infective, vitamins) in target markets increases wallet share from distributor partners. New product additions in Q4 would be positive.

5 Risks to Watch in BALAXI PHARMACEUTICALS Q4 FY26

Risk 1: Currency Depreciation in Target Markets

African and CIS currencies can depreciate significantly against USD, reducing USD-equivalent revenue.

Risk 2: Competition from Indian Generic Majors

Sun Pharma, Cipla, and Dr Reddy’s all export to Africa and emerging markets with larger product portfolios and established relationships.

Risk 3: Regulatory Approval Delays

Product registration in Africa can take 2-4 years. Delays in approvals push out revenue from new markets.

Risk 4: Payment Collection Risk

Emerging market healthcare distributors can have extended payment cycles, increasing receivable risk.

Risk 5: Supply Chain Disruptions

Export logistics to remote African markets face supply chain complexity and cost.

BALAXI PHARMACEUTICALS Share Price and Analyst Ratings

Parameter	Value
CMP (April 2026)	Rs 520
52-Week High	Rs 780
52-Week Low	Rs 460
1-Year Return	-30%
Market Capitalisation	Rs 720 Cr
Sector	Pharma Exports / Emerging Markets
NSE Ticker	BALAXI

Analyst ratings and target prices based on publicly available brokerage research:

Brokerage	Rating	Target Price	Investment Thesis
Anand Rathi	BUY	Rs 660	Africa pharma market growing 12% annually
Choice Broking	ADD	Rs 620	Branded generic premium sustainable

Conclusion

Balaxi Pharmaceuticals Q4 FY26 will reflect emerging market pharmaceutical demand trends. Revenue above Rs 185 crore with EBITDA margin above 13% would be a beat. The Africa and CIS export growth is the core thesis.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is BALAXI PHARMACEUTICALS Q4 results 2026 date?

BALAXI PHARMACEUTICALS Q4 FY26 results date is May 15, 2026. The board of directors will meet on this date to approve the quarterly and full-year FY26 financial results and consider recommending a final dividend.

Q: What is BALAXI PHARMACEUTICALS Q4 FY26 revenue estimate?

Analyst consensus estimate for BALAXI PHARMACEUTICALS Q4 FY26 revenue is Rs 185 Cr. Q3 FY26 actual revenue was Rs 162 Cr. Actual Q4 results may vary based on operating conditions.

Q: What is BALAXI PHARMACEUTICALS Q4 FY26 PAT estimate?

Analyst consensus estimate for BALAXI PHARMACEUTICALS Q4 FY26 net profit (PAT) is Rs 22 Cr. Q3 FY26 actual PAT was Rs 18 Cr. Estimates are indicative and not guaranteed.

Q: Will BALAXI PHARMACEUTICALS declare a dividend in Q4 FY26?

BALAXI PHARMACEUTICALS is expected to declare Rs 1 (expected) for FY26, subject to board approval at the May 15, 2026 board meeting and subsequent shareholder approval at the AGM.

Q: What is BALAXI PHARMACEUTICALS current share price?

BALAXI PHARMACEUTICALS is trading at Rs 520 as of April 2026, with a 52-week range of Rs 460 to Rs 780. The 1-year return is -30%.

Q: What were BALAXI PHARMACEUTICALS Q3 FY26 results?

In Q3 FY26, BALAXI PHARMACEUTICALS reported revenue of Rs 162 Cr and net profit (PAT) of Rs 18 Cr. The Q4 FY26 results on May 15, 2026 will provide a comparison to assess sequential and year-on-year trends.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026 (see the BALAXI PHARMACEUTICALS earnings calendar table above). Infosys is scheduled to declare results on April 23, 2026. Both are covered in detail on Univest Blogs.

Q: Is BALAXI PHARMACEUTICALS a good investment ahead of Q4 results?

This article does not constitute investment advice. BALAXI PHARMACEUTICALS trades at Rs 520 with a 52-week range of Rs 460 to Rs 780. Analyst consensus targets and the Q4 FY26 estimates suggest monitoring the results date closely. Consult a SEBI-registered financial advisor for personalised investment guidance.

Recent Article

Techno Electric & Engineering Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

JBM Auto Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Varroc Engineering Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Hitachi Energy India Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

CG Power and Industrial Solutions Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

News Q4 Results

Author: Neeraj Pandey

Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.